This session will feature a high-level panel discussion on Pharma 4.0, the next wave of transformational change in the biopharmaceutical industry. Pharma 4.0 leverages advanced technologies such as artificial intelligence, big data analytics, robotics, and the Internet of Things to create a more connected, agile, and patient-focused pharma landscape.
During this exclusive event, senior executives from leading and startup biopharmaceutical companies will gather to exchange insights, ideas, and best practices on embracing and implementing Pharma 4.0 to enhance patient outcomes, increase operational efficiency, and drive business growth. Industry experts will join us and will cover topics such as what Pharma 4.0 means to the Biopharmaceutical Industry, whether we are ready for Pharma 4.0, whether the technology is mature enough to be implemented, and what Pharma 4.0 means to the different players in this industry. Our lead research institute for biologics in Singapore will moderate the discussion.
Date: 22 May 2023
Time: 4:00pm – 6:00pm
4:00pm – 4:15pm: Registration
4:15pm – 4:20pm: Introduction and Welcome
4:20pm – 4:35pm: Presentation on Biopharma Landscape in Singapore – An EDB Perspective by Kane Cheong, Senior Manager, Singapore Economic Development Board
4:35pm – 4:50pm: Presentation on Advanced Analytics for Biotherapeutics by Davy Petit,Senior Director – Biologics Portfolio Owner, Waters Corporation (via virtual presence)
4:50pm – 5:30pm: Panel Discussion and Q&A with
- Dr Niki Wong, Director – Global Technical Operations CMC, AbbVie
- Dr Mark Polinkovsky, Head of Data Science Services, Arcondis (via virtual presence)
- Dr Alain Bouckenooghe, Chief Scientific Officer, Hilleman Laboratories
- Davy Petit, Senior Director – Biologics Portfolio Owner, Waters Corporation (via virtual presence)
- Moderator: A/Prof Andre Choo, Deputy Executive Director, A*STAR Bioprocessing Technology Institute
Dr Niki Wong, Director – Global Technical Operations CMC, AbbVie
Dr Niki Wong is the Director of the Global Technical Operations group in AbbVie Biologics Singapore, which oversees process development and tech transfer activities for biologics processes. She is also the CMC lead for a commercial frug substance programme. She has spent 11 years in AbbVie/Abbott, with prior roles as process and tech transfer leads. Her previous experience as a Research Scientist at the Bioprocessing Technology Institute involved various aspects of bioprocessing research, resulting in the co-authorship of 17 publications. Given her exposure to academia and industry, she is passionate about realising bioprocessing innovation in the industry.
Dr Mark Polinkovsky, Head of Data Science Services, Arcondis (via virtual presence)
With over 15 years of experience in applying novel technologies to solve complex problems, Mark is experienced in leading digital transformation and informatics projects. Mark has worked on multiple modernisation projects in academic labs, biotech startups, and global pharma companies, implementing IoT, AR / VR, and data systems with modern IT architectures to improve operations in laboratory and manufacturing environments.
Dr Alain Bouckenooghe, Chief Scientific Officer, Hilleman Laboratories
Dr Alain Bouckenooghe is currently the Chief Scientific Officer at Hilleman Laboratories, where he is leading the R&D department. He has worked in the pharmaceutical industry for over 20 years, mostly in vaccine R&D and regulatory and medical affairs. Alain obtained his Medical Degree at the Catholic University of Leuven, Belgium. Upon graduation, as a medical doctor, he worked for several years in a rural assignment as a District Medical Officer under the Ministry of Health of Zambia. Subsequently, Alain completed his residency in Internal Medicine at the University of Texas, Houston. He has a Master of Public Health degree from The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. He completed a Fellowship in Adult Infectious Diseases at Baylor College of Medicine, Houston, Texas. Alain held several academic positions during this time in the Department of Medicine at Baylor College.
After initial industry experience with MSD and GlaxoSmithKline Biologicals, he joined Sanofi Pasteur from December 2006 to 2018, covering various responsibilities, including Regional Head of Clinical R&D Asia Pacific, Regional Head of Medical Affairs, and as the R&D Partnership Lead in Asia. Alain joined MSD in 2018 as Associate VP leading the respiratory franchise in Global Clinical Development.
With the Hilleman Laboratories team, they aim to provide effective and affordable vaccine and biological solutions for Global Health problems, especially those impacting lower and middle-income countries.
Davy Petit, Senior Director – Biologics Portfolio Owner, Waters Corporation (via virtual presence)
Davy Petit is a driven commercial development executive with expertise in field marketing, sales force effectiveness and sales development with a strong drive for change management and cross-functional team leadership and development. He is focused on creating collaborative teams that outperform by working together to drive customer growth and value as a strategic thinker working on short and long-term business trends to apply continuously improved output.
In his newly appointed role as Senior Director - Biologics Portfolio Owner, he will be responsible for defining and implementing streamlined and integrated solutions that span the entire biologics spectrum from drug discovery to manufacturing, including state-of-the-art bioanalytical characterisation platforms, industry-leading systems and tools for optimising the development of cell lines, bioprocess unit operations and continuous manufacturing linked to monoclonal antibodies, multi-specifics, vaccines, nucleic acids, oligonucleotides and cell and gene therapies. Davy holds an MSc in analytical chemistry from the University of Antwerp and worked nine years in the pharmaceutical industry at Janssen Pharmaceuticals before joining Waters.
A/Prof Andre Choo, Deputy Executive Director, A*STAR Bioprocessing Technology Institute
A/Prof Andre Choo obtained his PhD from the University of Technology Sydney, focusing on the molecular engineering of antibody fragments and immunotoxins. He was also involved in identifying and characterising a monoclonal antibody that induced apoptosis of kappa-myelomas. This resulted in the formation of a spin-off company, HaemaLogiX, whose lead antibody is currently in Phase II clinical trials.
Returning to Singapore, he continued pursuing his interest in antibody discovery. He was responsible for discovering mAb 84, a first-in-class antibody that selectively kills undifferentiated pluripotent stem cells making cell therapy safer. Leveraging on in-house expertise, he nucleated the Antibody Discovery Platform (ADP) to focus on discovering and characterising new biologics for cell separation and diagnostic and therapeutic applications against stem cells and cancer cells. Their lead oncology asset, EBC-129, was approved in Jan 2023 by the US FDA and Singapore’s HSA for first-in-man clinical trials. This is the first made-in-Singapore antibody-drug conjugate.
He is Deputy Executive Director and Group Leader at the Bioprocessing Technology Institute (BTI), Executive Director at the Biomedical Research Council, A*STAR and Adjunct Professor at the Department of Biomedical Engineering, National University of Singapore.